Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Five questions for Novartis India's MD

This article was originally published in Scrip

Executive Summary

Novartis India's vice chairman and managing director Ranjit Shahani once joked that almost every passenger even on a "Virar fast local" knows about the company and its anticancer, Glivec (imatinib mesylate), with the backdrop of the Supreme Court ruling last year rejecting a patent for the product and high decibel allegations by activists that the Swiss company was attempting to get the legal framework for examining patent applications in India relaxed.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts